Eagle Pharms patents expiration
1. Argatroban In Sodium Chloride patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7589106 | EAGLE PHARMS | Alcohol free formulation of argatroban |
Sep, 2027
(3 years from now) | |
| US7687516 | EAGLE PHARMS | Alcohol free formulation of argatroban |
Sep, 2027
(3 years from now) | |
Drugs and Companies using ARGATROBAN ingredient
Market Authorisation Date: 29 June, 2011
Treatment: Method of treating thrombosis; Method of treating an argatroban treatable condition
Dosage: INJECTABLE;INTRAVENOUS
ARGATROBAN IN SODIUM CHLORIDE family patents
2. Belrapzo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
| US9572796 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(7 years from now) | |
| US9572797 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(7 years from now) | |
| US11103483 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(7 years from now) | |
| US10010533 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(7 years from now) | |
| US9265831 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(7 years from now) | |
| US8609707 | EAGLE PHARMS | Formulations of bendamustine |
Aug, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | Dec 7, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 May, 2018
Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma
Dosage: SOLUTION;IV (INFUSION)
BELRAPZO family patents
3. Bendeka patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
| US9572797 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(7 years from now) | |
| US9572796 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(7 years from now) | |
| US11103483 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(7 years from now) | |
| US10010533 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(7 years from now) | |
| US9265831 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(7 years from now) | |
| US8609707 | EAGLE PHARMS | Formulations of bendamustine |
Aug, 2031
(7 years from now) | |
| US9572887 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(9 years from now) | |
| US9579384 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(9 years from now) | |
| US9000021 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(9 years from now) | |
| US9597398 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(9 years from now) | |
| US9034908 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(9 years from now) | |
| US9597397 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(9 years from now) | |
| US10052385 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(9 years from now) | |
| US9597399 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(9 years from now) | |
| US9144568 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 7, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2015
Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma; For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients w...
Dosage: SOLUTION;IV (INFUSION)
BENDEKA family patents
4. Pemfexy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9604990 | EAGLE PHARMS | Crystalline forms of pemetrexed diacid and manufacturing processes therefor |
Oct, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7772209 | EAGLE PHARMS | Antifolate combination therapies |
May, 2022
(1 year, 6 months ago) | |
| US11793813 | EAGLE PHARMS | Pemetrexed formulations |
Feb, 2036
(12 years from now) | |
Drugs and Companies using PEMETREXED ingredient
Market Authorisation Date: 08 February, 2020
Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with mesothelioma; Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administra...
Dosage: SOLUTION;INTRAVENOUS
PEMFEXY family patents
5. Ryanodex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9884044 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2022
(1 year, 5 months ago) | |
| US8604072 | EAGLE PHARMS | Treatment using dantrolene |
Jul, 2022
(1 year, 4 months ago) | |
| US8110225 | EAGLE PHARMS | Treatment using dantrolene |
Dec, 2022
(11 months ago) | |
| US8685460 | EAGLE PHARMS | Treatment using dantrolene |
Feb, 2023
(9 months ago) | |
| US7758890 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2025
(1 year, 6 months from now) | |
Drugs and Companies using DANTROLENE SODIUM ingredient
Market Authorisation Date: 22 July, 2014
Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.
Dosage: FOR SUSPENSION;INTRAVENOUS
RYANODEX family patents